Hassane Lab

Overview

dhassane2Duane C. Hassane, Ph.D. is an Assistant Professor of Computational Biomedicine in the Department of Medicine and the Institute for Computational Biomedicine at Weill Cornell Medical College in New York City, leading the Translational Genomics Program in Hematologic Malignancies.

Dr. Hassane graduated from the University of Rochester where he received undergraduate and graduate degrees in Microbiology and Virology, then receiving his Ph.D. from the University of Kentucky School of Medicine in Microbiology, Immunology, and Molecular Genetics. He subsequently completed post-doctoral training in the laboratory of Dr. Craig Jordan at the University of Rochester School of Medicine using advanced genomic approaches to rationally develop unique pre-clinical single agent and combination therapies for leukemia.

Dr. Hassane is the principal investigator or co-investigator on grants from the Leukemia and Lymphoma Society and the National Institutes of Health and has authored or co-authored high impact peer-reviewed manuscripts and book chapters. His findings have been presented and highlighted at international meetings.

Dr. Hassane’s laboratory aims to understand the genetic heterogeneity of leukemia, myelodysplastic syndromes, and myeloproliferative disease to improve monitoring and control of relapse and disease progression. His efforts employ a variety of state-of-the-art technologies, including massively parallel gene sequencing. This work pushes the power of genomics, including pharmacogenomics and genome sequencing, to develop new ways to improve cancer treatment by understanding and modulating the genes and gene networks that drive cancer and the way cancer responds to drugs.

With a major focus on leukemia research, Dr. Hassane combines laboratory experiments and state-of-the-art genomic analytics to address critical challenges in overcoming drug resistance, preventing relapse, avoiding secondary malignancies, and ablating cancer stem cells. 

His research is applied in Weill Cornell’s minimal residual disease and precision medicine programs, building the next generation of advanced diagnostics for leukemia.

Learn more about Dr. Hassane’s research and his team.